Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1389 | 1089 | 1593 | 1750 | 3459 | 3466 |
Fund Return | 38.93% | 8.89% | 59.27% | 20.5% | 28.17% | 13.23% |
Place in category | 34 | 37 | 37 | 35 | 39 | 20 |
% in Category | 34 | 31 | 39 | 43 | 68 | 100 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UTI Equity Fund Growth | 259.24B | 13.24 | 5.79 | 12.54 | ||
UTI Equity Fund Dividend Payout | 259.24B | 13.24 | 5.76 | 12.42 | ||
UTI Equity Fund Growth Option D | 259.24B | 13.92 | 6.62 | 13.23 | ||
UTI Equity Fund Income Option D | 259.24B | 13.92 | 6.60 | 13.11 | ||
UTI Master Share Growth Option Dire | 139.87B | 13.46 | 11.01 | 12.96 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Pharma Fund - Bonus | 86.89B | 30.90 | 19.84 | 15.52 | ||
Reliance Pharma Dividend Payout | 86.89B | 29.93 | 21.25 | 16.57 | ||
Reliance Pharma Fund - Growth | 86.89B | 30.90 | 19.84 | 15.52 | ||
Reliance Pharma Direct Bonus | 86.89B | 31.89 | 20.92 | 16.54 | ||
Reliance Pharma Direct Growth | 86.89B | 31.89 | 20.92 | 16.54 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Sun Pharma | INE044A01036 | 11.29 | 1,795.30 | +0.86% | |
Cipla | INE059A01026 | 5.89 | 1,486.50 | +1.43% | |
Ajanta Pharma Ltd | INE031B01049 | 5.38 | 2,960.05 | +0.49% | |
Dr Reddy’s Laboratories | INE089A01031 | 4.67 | 1,214.45 | +1.60% | |
Gland | INE068V01023 | 3.70 | 1,755.05 | -1.79% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Sell | BUY | Strong Buy |
Summary | Neutral | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review